Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Ip2Ipo Innovations Limited is managing 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These cases are distributed across 5 distinct art units, showing a relatively high degree of technical specialization within the sector. The prosecution involves 6 distinct examiners, ensuring that each pending action is handled by a different individual. This distribution requires the company to manage 6 separate examiner relationships across 5 different technical groups.
Kimberly Catherine Breen is the busiest examiner for this portfolio, with 1 pending office action under her review. The presence of 6 distinct examiners for 6 actions indicates that no examiner is currently handling multiple cases for the company. This distribution across 5 distinct art units suggests that the portfolio's pharmaceutical or biotech innovations are being evaluated by a wide variety of subject matter experts. Practitioners should be prepared for a diverse range of feedback, as the lack of examiner concentration limits the ability to apply a single successful strategy across multiple pending matters. Navigating 5 distinct art units requires a deep understanding of the specific standards and precedents relevant to each technical area.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (33%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BREEN, KIMBERLY CATHERINE | 1 | 23.8% | +56.9% |
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| LI, RUIXIANG | 1 | 59.5% | +18.6% |
| HUANG, MICKEY NMN | 1 | 59.6% | +49.2% |
| SHARPLESS, CHRISTEN ALICIA | 1 | 50.4% | +27.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18817094 | Rhinovirus Vaccine | SIFFORD, JEFFREY MARK | 81d overdue |
| 17430639 | METHOD FOR DIAGNOSING OESOPHAGOGASTRIC CANCER | HUANG, MICKEY NMN | 16d overdue |
| 18827601 | DETECTION OF CREATINE LEVELS USING ENZYME COMPOSITIONS | BREEN, KIMBERLY CATHERINE | — |
| 17264673 | A JOINT | SHARPLESS, CHRISTEN ALICIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18817094 | Rhinovirus Vaccine | SIFFORD, JEFFREY MARK | 81d overdue |
| 17430639 | METHOD FOR DIAGNOSING OESOPHAGOGASTRIC CANCER | HUANG, MICKEY NMN | 16d overdue |
| 18827601 | DETECTION OF CREATINE LEVELS USING ENZYME COMPOSITIONS | BREEN, KIMBERLY CATHERINE | — |
| 18028498 | ZIP12 ANTIBODY | LI, RUIXIANG | — |
| 17264673 | A JOINT | SHARPLESS, CHRISTEN ALICIA | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1672 | 1 |
| 1674 | 1 |
| 1758 | 1 |
| 3795 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18827601 | DETECTION OF CREATINE LEVELS USING ENZYME COMPOSITIONS | BREEN, KIMBERLY CATHERINE | — | §103§112 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18817094 | Rhinovirus Vaccine | SIFFORD, JEFFREY MARK | 1671 | §101§103 | Final Rejection | 81d overdue | Pending | Aug 27, 2024 |
| 18456354 | RETROVIRAL VECTORS | ALAM, DANYAL HASSAN | 1672 | §102§103§112DP | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18028498 | ZIP12 ANTIBODY | LI, RUIXIANG | 1674 | §112 | Non-Final OA | — | Pending | Mar 24, 2023 |
| 17430639 | METHOD FOR DIAGNOSING OESOPHAGOGASTRIC CANCER | HUANG, MICKEY NMN | 1758 | §101§103 | Final Rejection | 16d overdue | Pending | Aug 12, 2021 |
| 17264673 | A JOINT | SHARPLESS, CHRISTEN ALICIA | 3795 | §102§103 | Non-Final OA | — | Pending | Jan 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial